147025-53-4C#CCO[C@H]1CN2CCC1CC2XVFJONKUSLSKSW-JTQLQIEISA-NTalsaclidine has been used in trials studying the treatment of Alzheimer Disease.
147025-53-4DTXSID20163565CHEMBL2111051Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
P264+P265, P280, P305+P354+P338, and P317 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory.
UsesTalsaclidine, a novel M1-receptor selective muscarinic agonist for cholinergic substitution therapy of Alzheimer''s disease. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer''s disease.
No reaction records under the current filter.
Loading…